Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life ...

Shares of Bio-Techne Corp. TECH rose 1.01% to $52.00 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.15% to 6,581.00 and ...

Bio-Techne (TECH) is back in focus after institutional investors such as Jefferies Financial Group and Madison Investments ...

Madison Investments, an investment advisor, released its fourth-quarter 2025 investor letter for “Madison Mid Cap Fund”. A copy of the letter can be downloaded here. The Russell Midcap Index ended an ...

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...

Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...

Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...

The collaboration between Leica Biosystems and Bio-Techne expands access to advanced RNA ISH technology for clinical ...

Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...